Center for Scientific Review; Notice of Closed Meeting, 37556 [2013-14815]

Download as PDF TKELLEY on DSK3SPTVN1PROD with NOTICES 37556 Federal Register / Vol. 78, No. 120 / Friday, June 21, 2013 / Notices essential cells to remain unharmed. Thus, monoclonal antibodies to GPC3 (and corresponding immunotoxins) represent a novel therapeutic candidate for treatment of HCC, as well as other cancers associated with the differential expression of GPC3. Potential Commercial Applications: • Therapeutic antibodies against cancers that overexpress GPC3. • Therapeutic immunotoxins or antibody-drug conjugates for killing cancer cells that overexpress GPC3. • Diagnostics for detecting cancers associated with GPC3 overexpression. • Specific cancers include hepatocellular cancer (HCC), melanoma, ovarian cancer, thyroid cancer, lung squamous cell carcinoma, Wilms’ tumor, neuroblastoma, hepatoblastoma, and testicular germ-cell tumors. Competitive Advantages: • Monoclonal antibodies create a level of specificity that can reduce deleterious side-effects. • Multiple treatment strategies available including the killing of cancer cells with a toxic agent or by inhibiting cell signaling. • Non-invasive and potentially nonliver toxic alternative to current HCC treatment strategies. Development Stage: • Pre-clinical. • In vitro data available. • In vivo data available (animal). Inventors: Mitchell Ho (NCI) et al. Publications: 1. Feng M, et al. Therapeutically targeting glypican-3 via a conformationspecific single-domain antibody in hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):E1083–91. [PMID 23471984] 2. Feng M, et al. Recombinant soluble glypican 3 protein inhibits the growth of hepatocellular carcinoma in vitro. Int J Cancer 2011 May1;128(9):2246–7. [PMID: 20617511] 3. Zitterman SI, et al. Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. Int J Cancer 2010 Mar 15;126(6):1291–1301. [PMID: 19816934] Intellectual Property: HHS Reference No. E–130–2011/0—U.S. Provisional Application No. 61/477,020 filed 19 Apr 2011; PCT Application No. PCT/ US2012/034186 filed 19 Apr 2012. Related Technology: HHS Reference No. E–136–2012/0—U.S. Provisional Application No. 61/654,232 filed 01 Jun 2012. Licensing Contact: David A. Lambertson, Ph.D.; 301–435–4632; lambertsond@mail.nih.gov. Collaborative Research Opportunity: The National Cancer Institute, Center for Cancer Research, Laboratory of VerDate Mar<15>2010 18:32 Jun 20, 2013 Jkt 229001 Molecular Biology, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize novel antibody or antibody-drug conjugate therapies for the treatment of liver cancer. For collaboration opportunities, please contact John Hewes, Ph.D. at hewesj@mail.nih.gov. Dated: June 14, 2013. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 2013–14821 Filed 6–20–13; 8:45 am] BILLING CODE 4140–01–P Extramural Research, National Eye Institute, National Institutes of Health, 5635 Fishers Lane, Suite 1300, MSC 9300, 301–451–2020, hoshawb@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.867, Vision Research, National Institutes of Health, HHS) Dated: June 17, 2013. Melanie J. Gray, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2013–14816 Filed 6–20–13; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Eye Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Eye Institute Special Emphasis Panel; NEI Epidemiology and Genetics. Date: July 10, 2013. Time: 11:30 a.m. to 2:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 5635 Fishers Lane, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Anne E. Schaffner, Ph.D., Chief, Scientific Review Officer, Division of Extramural Research, National Eye Institute, National Institutes of Health, 5635 Fishers Lane, Suite 1300, MSC 9300, 301–451–2020, aes@nei.nih.gov. Name of Committee: National Eye Institute Special Emphasis Panel; NEI Institutional Training Grants and Conference Grants. Date: July 30, 2013. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Terrace Level Conference Center, 5635 Fishers Lane, Bethesda, MD 20892. Contact Person: Brian Hoshaw, Ph.D., Scientific Review Branch, Division of PO 00000 Frm 00053 Fmt 4703 Sfmt 9990 Center for Scientific Review; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; RFA Panel: Molecular and Cellular Substrates of Complex Brain Disorders. Date: July 19, 2013. Time: 8:00 a.m. to 5:30 p.m. Agenda: To review and evaluate grant applications. Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road NW., Washington, DC 20015. Contact Person: Deborah L Lewis, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4183, MSC 7850, Bethesda, MD 20892, 301–408– 9129, lewisdeb@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: June 14, 2013. Anna Snouffer, Deputy Director, Office of Federal Advisory Committee Policy. [FR Doc. 2013–14815 Filed 6–20–13; 8:45 am] BILLING CODE 4140–01–P E:\FR\FM\21JNN1.SGM 21JNN1

Agencies

[Federal Register Volume 78, Number 120 (Friday, June 21, 2013)]
[Notices]
[Page 37556]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-14815]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Center for Scientific Review; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; RFA Panel: Molecular and Cellular Substrates of Complex Brain 
Disorders.
    Date: July 19, 2013.
    Time: 8:00 a.m. to 5:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military 
Road NW., Washington, DC 20015.
    Contact Person: Deborah L Lewis, Ph.D., Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 4183, MSC 7850, Bethesda, MD 
20892, 301-408-9129, lewisdeb@csr.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, 
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, 
National Institutes of Health, HHS)

    Dated: June 14, 2013.
Anna Snouffer,
Deputy Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2013-14815 Filed 6-20-13; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.